Top 100 Therapeutics Startups to Watch in 2026
The therapeutics sector is seeing major investment across many areas of health. Companies are tackling everything from cancer treatment to mental healthcare access.
For example, Avenzo Therapeutics has raised over $841 million for oncology since 2022. The field also includes companies like Midi Health, which focuses on virtual care for women.
Below is our list of 100 Therapeutics startups worth keeping an eye on.
Failory's Top 10 Picks
Odyssey Therapeutics creates precision medicines to treat patients with cancer and inflammatory diseases. Their discovery platform combines machine learning with deep expertise in biology and chemistry to develop novel immunomodulators and oncology drugs.
| Headquarters | Cambridge, Massachusetts, United States |
| Year Founded | 2021 |
| Founders | David Pompliano, Gary Glick |
| Funding Amount | $700M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series D |
| Top Investors | TPG, General Catalyst, OrbiMed, Lightspeed Venture Partners, Catalio Capital Management |
Midi Health built a virtual care platform to support women through menopause and other midlife health transitions. The service connects patients with trained clinicians who provide personalized treatment for hormonal changes and related conditions.
| Headquarters | Los Angeles, California, United States |
| Year Founded | 2021 |
| Founders | Joanna Strober, Sharon Meers |
| Funding Amount | $152M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series C |
| Top Investors | Felicis, GV, Muse Capital, Operator Collective, Emerson Collective |
Enveda Biosciences develops novel medications by exploring the chemical compounds found in plants. Their drug discovery platform uses machine learning to identify promising molecules for new therapeutics.
| Headquarters | Boulder, Colorado, United States |
| Year Founded | 2019 |
| Founders | Viswa Colluru |
| Funding Amount | $529.9M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series D |
| Top Investors | Village Global, Lux Capital, Catalio Capital Management, Sanofi, FPV Ventures |
Headway builds a mental healthcare system that makes it easier for patients to find a therapist who accepts their insurance. Their platform also helps providers by enabling them to accept insurance and scale their private practices.
| Headquarters | New York, New York, United States |
| Year Founded | 2019 |
| Founders | Andrew Adams, Dan Ross, Jake Sussman, Kevin Chan |
| Funding Amount | $325.5M |
| Startup Size | Large Team (251-1,000) |
| Last Funding Status | Series D |
| Top Investors | Andreessen Horowitz, Accel, Forerunner, Thrive Capital, Bossa Invest |
Avenzo Therapeutics develops targeted oncology therapies designed to treat various forms of cancer. The company focuses on advancing its clinical pipeline to provide new options for patients with unmet medical needs.
| Headquarters | San Diego, California, United States |
| Year Founded | 2022 |
| Founders | Athena Countouriotis, Mohammad Hirmand |
| Funding Amount | $841.9M |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Series B |
| Top Investors | OrbiMed, New Enterprise Associates, INCE Capital, SR One, Lilly Asia Ventures |
Character Biosciences built a platform that merges genomics, clinical data, and AI to find new ways to treat complex diseases. Their work currently focuses on Age-related Macular Degeneration (AMD), aiming to develop novel diagnostics and therapeutics for patients.
| Headquarters | Jersey City, New Jersey, United States |
| Year Founded | 2018 |
| Founders | Cheng Zhang, Marcel van der Brug |
| Funding Amount | $137M |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Series B |
| Top Investors | Catalio Capital Management, Industry Ventures, S32, Cantos, Casdin Capital |
CHARM Therapeutics applies 3D deep learning to discover and develop novel small molecule medicines against difficult-to-drug targets. Their proprietary platform, DragonFold, powers a lead program in oncology that targets a key protein interaction driving acute leukemias.
| Headquarters | London, England, United Kingdom |
| Year Founded | 2021 |
| Founders | David Baker, Laksh Aithani |
| Funding Amount | $162.7M |
| Startup Size | Lean Team (11-50) |
| Last Funding Status | Series B |
| Top Investors | General Catalyst, OrbiMed, NVIDIA, Khosla Ventures, New Enterprise Associates |
SetPoint Medical develops a bioelectronic medicine platform to treat chronic autoimmune diseases. Their proprietary device stimulates the vagus nerve, offering a new therapeutic approach for conditions like rheumatoid arthritis as an alternative to drug therapy.
| Headquarters | Valencia, California, United States |
| Year Founded | 2007 |
| Founders | Jim Broderick, Kevin Tracey, Shaw Warren |
| Funding Amount | $496.4M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series D |
| Top Investors | Norwest Venture Partners, New Enterprise Associates, Catalio Capital Management, Boston Scientific, Elevage Medical Technologies |
Grow Therapy created a mental health marketplace that connects patients with therapists who match their needs and insurance. The platform empowers therapists by handling administrative tasks like booking and billing, allowing them to launch and grow their own private practices.
| Headquarters | New York, New York, United States |
| Year Founded | 2020 |
| Founders | Alan Ni, Jake Cooper, Manoj Kanagaraj |
| Funding Amount | $178M |
| Startup Size | Large Team (251-1,000) |
| Last Funding Status | Series C |
| Top Investors | Village Global, Sequoia Capital, Goldman Sachs, TCV, Transformation Capital |
Massive Bio built an AI-powered platform to connect cancer patients with personalized clinical trial options. Their service helps patients access advanced treatments while allowing pharmaceutical companies to more easily find participants for oncology research.
| Headquarters | New York, New York, United States |
| Year Founded | 2015 |
| Founders | Arturo Loaiza-Bonilla, Cagatay Culcuoglu, Selin Kurnaz |
| Funding Amount | $23.8M |
| Startup Size | Mid-Size Team (51-250) |
| Last Funding Status | Series B |
| Top Investors | 500 Global, Revo Capital, 500 Emerging Europe, Princeton Alumni Angels, ImpactAssets |
90 Additional Therapeutics Startups Worth Following
Those top 10 companies are just a small slice of what’s happening in the field. A huge number of new startups are focused on biotech and AI to develop new treatments.
In total, the companies on our list have raised over $15 billion, showing a big vote of confidence from investors. Here’s a look at the other startups that are pushing the industry forward.
| Startup | Main Industry | Year Founded | Amount Raised | Last Funding Round |
|---|---|---|---|---|
 Sparrow Pharmaceuticals | Biotech | 2013 | $156.3M | Series B |
 Galvanize Therapeutics | Healthcare | 2015 | $248.5M | Series C |
 Skyhawk Therapeutics | Biotech | 2016 | $181.2M | Venture Round |
 Star Therapeutics | Healthcare | 2018 | $315M | Series D |
 Sword Health | AI | 2015 | $493.5M | Venture Round |
 Cellares | Biotech | 2019 | $355M | Series C |
 Mercy BioAnalytics | Biotech | 2018 | $127.3M | Series B |
 Ensoma | Biotech | 2019 | $258M | Venture Round |
 Presence | Education | 2009 | $414.2M | Private Equity |
 Strand Therapeutics | Biotech | 2017 | $257.2M | Series B |
 Enlaza Therapeutics | Biotech | 2020 | $180M | Venture Round |
 Seed Health | Biotech | 2016 | $40M | Series A |
 Predicta Biosciences | Biotech | 2023 | $28.6M | Series A |
 Elektrofi | Healthcare | 2016 | $154.1M | Series C |
 Retro Biosciences | Biotech | 2021 | $180M | Angel |
 Iambic | AI | 2019 | $203M | Series B |
 Scribe Therapeutics | Biotech | 2017 | $120M | Convertible Note |
 Wugen | Biotech | 2018 | $287M | Series C |
 Tahoe Therapeutics | AI | 2022 | $42M | Series A |
 Opus Genetics | Biotech | 2004 | $22.7M | Grant |
 HAYA Therapeutics | Biotech | 2017 | $1.1B | Grant |
 Click Therapeutics | Biotech | 2012 | $1B | Series C |
 Orbital Therapeutics | Healthcare | 2022 | $270M | Series A |
 Replicate Bioscience | Biotech | 2020 | $46M | Series A |
 Leal Therapeutics | Healthcare | 2021 | $75M | Series A |
 Dewpoint Therapeutics | Biotech | 2018 | $346.1M | Series D |
 Interius BioTherapeutics | Biotech | 2019 | $175.9M | Undisclosed |
 INBRAIN Neuroelectronics | Biotech | 2020 | $119.8M | Grant |
 Swing Therapeutics | Biotech | 2019 | $34M | Undisclosed |
 Centivax | Biotech | 2020 | $59.2M | Series A |
 Epigenic Therapeutics | Biotech | 2021 | $122M | Series B |
 PhaseV | AI | 2023 | $65M | Series A |
 Blueprint | AI | 2019 | $32.3M | Venture Round |
 Circle Pharma | Biotech | 2012 | $207.5M | Series D |
 Boulder Care | Healthcare | 2017 | $85.2M | Series C |
 Alcyone Therapeutics | Biotech | 2010 | $23M | Corporate Round |
 Prellis Biologics | Manufacturing | 2016 | $79.4M | Series C |
 Noctrix Health | Healthcare | 2018 | $90.5M | Venture Round |
 Leyden Labs | Biotech | 2020 | $315.2M | Venture Round |
 Spark Biomedical | Healthcare | 2018 | $32.8M | Grant |
 Maxion Therapeutics | Healthcare | 2020 | £73M | Series A |
 C2N Diagnostics | Biotech | 2007 | $85.7M | Corporate Round |
 NextRNA Therapeutics | Biotech | 2020 | $56.1M | Series A |
 Dispatch Bio | Biotech | 2022 | $216M | Series A |
 Crystalys Therapeutics | Biotech | 2025 | $205M | Series A |
 Sonoma Biotherapeutics | Biotech | 2020 | $365M | Corporate Round |
 Atavistik Bio | Biotech | 2021 | $100M | Venture Round |
 Orna Therapeutics | Biotech | 2019 | $321M | Series B |
 Seed Therapeutics | Biotech | 2019 | $30M | Series A |
 Atsena Therapeutics | Biotech | 2019 | $237.6M | Series C |
 Slingshot Biosciences | Biotech | 2012 | $64.2M | Series A |
 Pretzel Therapeutics | Biotech | 2019 | $72.5M | Venture Round |
 Xaira Therapeutics | AI | 2023 | $1B | Series A |
 Incyclix Bio | Biotech | 2020 | $47.2M | Series B |
 Brightside Health | Healthcare | 2017 | $114.4M | Series C |
 BigHat Biosciences | AI | 2019 | $99.3M | Series B |
 Woebot Health | AI | 2017 | $123.3M | Venture Round |
 Remedium Bio | Biotech | 2020 | $2.3M | Corporate Round |
 Nusano | Biotech | 2013 | $115M | Series C |
 Polaris Genomics | Biotech | 2017 | $5.6M | Debt Financing |
 Vida Health | Healthcare | 2014 | $216.5M | Venture Round |
 BioTissue | Biotech | 2001 | $110M | Series C |
 MOMA Therapeutics | Biotech | 2020 | $236M | Series B |
 Insitro | Biotech | 2018 | $643M | Series C |
 SonderMind | Healthcare | 2014 | $183M | Series C |
 Cellvie | Biotech | 2018 | $15.5M | Seed |
 1910 Genetics | AI | 2018 | $26.7M | Venture Round |
 GT Medical Technologies | Healthcare | 2017 | $162.5M | Series D |
 Mabylon | Biotech | 2015 | CHF31.3M | Convertible Note |
 Pathos | AI | 2020 | $447M | Series D |
 SpectrumAi | Sports | 2021 | $29M | Series A |
 Candid Therapeutics | Biotech | 2024 | $370M | Series A |
 Nutcracker Therapeutics | Biotech | 2018 | $241M | Series C |
 SK biopharmaceuticals | Biotech | 2011 | $180M | Grant |
 Envisagenics | AI | 2014 | $52.1M | Series B |
 Ashvattha Therapeutics | Biotech | 2015 | $148M | Series B |
 Judo Bio | Biotech | 2021 | $100M | Series A |
 Draig Therapeutics | Biotech | 2024 | $140M | Series A |
 Epitopea | Biotech | 2021 | $44.8M | Seed |
 Capstan Therapeutics | Biotech | 2021 | $340M | Series B |
 Saluda Medical | Healthcare | 2010 | $499.5M | Venture Round |
 AbsoluteCARE | Healthcare | 2000 | $252M | Private Equity |
 Allay Therapeutics | Biotech | 2017 | $149.5M | Series D |
 ResBiotic | Biotech | 2018 | $16.1M | Series A |
 Ansa Biotechnologies | Biotech | 2018 | $128.6M | Series B |
 Nuvig Therapeutics | Biotech | 2021 | $208M | Series B |
 Alltrna | Biotech | 2018 | $159M | Series B |
 BlossomHill Therapeutics | Biotech | 2020 | $173M | Series B |
 Cartwheel | Healthcare | 2022 | $55.2M | Series B |
 Talus Bio | AI | 2020 | $27.8M | Seed |
